Alkermes to Present New Alixorexton and LUMRYZ Data at Sleep Europe 2026
Alkermes plc (NASDAQ:ALKS) plans to present new clinical findings for its sleep medicine portfolio at the Sleep Europe 2026 congress in Maastricht, Netherlands, scheduled for October 20-23. The presentations will feature two oral talks and six posters covering key study results for alixorexton and LUMRYZ. Shares of Alkermes were trading down 0.86% at $40.26 following the announcement.
The upcoming presentations highlight detailed data from the Phase 3 REVITALYZ study of LUMRYZ in adults with idiopathic hypersomnia, alongside long-term Phase 2 extension results for alixorexton in patients with narcolepsy types 1 and 2. Alixorexton is an investigational drug that has received Breakthrough Therapy and Orphan Drug designations from regulators. LUMRYZ became part of the portfolio through the acquisition of Avadel Pharmaceuticals plc, though marketing for idiopathic hypersomnia is restricted until at least March 1, 2028 under a settlement agreement.
Investors and healthcare providers will look to the detailed conference findings for further validation of alixorexton safety and long-term durability. Attention will also turn to the ongoing Phase 3 Brilliance trials evaluating alixorexton in narcolepsy, as Alkermes works to advance its pipeline in sleep disorders.
Key points
- Alkermes plc (NASDAQ:ALKS) will deliver two oral presentations and six poster sessions at the Sleep Europe 2026 conference from Oct. 20-23, 2026.
- Presentations feature Phase 3 trial results for LUMRYZ in idiopathic hypersomnia and long-term extension data for alixorexton in narcolepsy.
- Alixorexton is an experimental selective orexin 2 receptor agonist currently undergoing Phase 3 clinical evaluation.
- Alkermes cannot market LUMRYZ for idiopathic hypersomnia prior to March 1, 2028, under a settlement agreement.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What treatments is Alkermes presenting data on at Sleep Europe 2026?
Alkermes is presenting research on alixorexton, an investigational drug for narcolepsy and idiopathic hypersomnia, and LUMRYZ extended-release oral suspension for sleep disorders.
When will Alkermes present its study results at Sleep Europe 2026?
The company is scheduled to deliver presentations and poster sessions during the congress held from Oct. 20 to Oct. 23, 2026, in Maastricht, Netherlands.
Can Alkermes market LUMRYZ for idiopathic hypersomnia immediately?
No, Alkermes cannot market or promote LUMRYZ for idiopathic hypersomnia before March 1, 2028, due to the terms of a settlement and license agreement.